Institutional Biosafety Committee (IBC)

A standing institutional committee, registered with the NIH Office of Science Policy under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, that reviews, approves, and provides ongoing oversight of research involving recombinant or synthetic nucleic acid molecules before such research may begin.

ByCASRAI Editorial Board

· Last updated 18 Jul 2026

Worked examples

Is an instance

A university molecular biology lab plans to create a recombinant lentiviral vector expressing a fluorescent reporter gene. Before ordering reagents or beginning bench work, the PI registers the protocol with the IBC, which assigns it to NIH Guidelines Section III-D, confirms BSL-2 containment, and issues approval.

Is an instance

An institution's IBC receives an amendment request adding a new viral vector with broader tropism to an already-approved protocol. Because the change could increase risk, the IBC requires re-review and revised containment measures before the amendment may proceed, rather than treating it as a routine notification.

Looks similar, but isn't

Not an instance

A study using only naturally occurring, non-recombinant microorganisms with no genetic modification generally does not require IBC review under the NIH Guidelines, even though it may still require institutional biosafety review under BMBL-based policy or, for select agents, the Federal Select Agent Program.

Not an instance

A purely computational (in silico) analysis of published genomic sequence data, with no physical construction or handling of recombinant or synthetic nucleic acid molecules, falls outside IBC jurisdiction.

The Institutional Biosafety Committee (IBC) is the standing institutional body the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules require every covered institution to establish and maintain. No research involving recombinant or synthetic nucleic acid (r/sNA) molecules that the Guidelines cover may begin until the IBC has reviewed and approved (or, for lower-risk categories, been notified of) the protocol. Structurally and functionally, the IBC sits alongside the IRB and the IACUC as one of the three core protocol-review committees a US research institution maintains — the IRB for human subjects, the IACUC for vertebrate animal research, and the IBC for recombinant/synthetic nucleic acid work and, at most institutions, biological materials more broadly.

What Makes a Committee an IBC

An IBC is not simply any internal safety group — it is a specific, formally constituted committee that meets the NIH Guidelines’ registration and composition requirements and has been registered with the NIH Office of Science Policy (OSP). Three things define an IBC as such:

Registration. The institution registers its IBC, including its membership roster, with NIH OSP through the IBC Registration system. Registration is a precondition for conducting most categories of r/sNA research the Guidelines cover.
Minimum composition. At least five members, collectively qualified by training and experience to assess the safety of recombinant/synthetic nucleic acid research and to identify risks to public health or the environment, including at least two members unaffiliated with the institution (apart from IBC service) who represent the surrounding community’s health and environmental interests.
Review authority. The IBC has the authority to approve, require modification of, or disapprove covered research, to assign or confirm the biosafety containment level for a protocol, to require re-review when a protocol changes in a way that could increase risk, and to report significant problems, violations, and NIH Guidelines-reportable incidents to NIH OSP.

What the IBC Actually Does

In practice, an active IBC performs four recurring functions:

Protocol registration and review. Every covered r/sNA project is registered with the IBC before work starts. The committee assigns the project’s NIH Guidelines Section III risk category and confirms the required biosafety containment level, commonly by reference to the Biosafety Level (BSL) framework in the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) manual.
Facility inspection. IBCs periodically inspect laboratory containment facilities and practices for compliance with the assigned biosafety level.
Ongoing and amendment review. Any change to an approved protocol that could increase risk — a new agent, a new vector, a new route of exposure, a higher-risk host organism — triggers IBC re-review before the change may be implemented.
Dual-use and biosecurity screening. At institutions conducting relevant life-sciences research, the IBC (or a closely linked institutional biosecurity/DURC review process) screens protocols against the criteria for Dual-Use Research of Concern (DURC) and, where applicable, the federal P3CO (Potential Pandemic Pathogen Care and Oversight) framework for enhanced potential pandemic pathogens.

Human Gene Transfer Protocols

Human gene transfer research is a specific, more heavily scrutinized subset of IBC work. Under NIH Guidelines Section III-C, the IBC approves human gene transfer protocols and, for certain categories, coordinates with NIH OSP; historically this also involved the NIH Recombinant DNA Advisory Committee (RAC) for the highest-visibility protocols, a role that has narrowed over successive revisions of the Guidelines as the field matured. The IBC’s approval of a human gene transfer protocol operates alongside — not instead of — required FDA and IRB review for the same clinical protocol.

IBC, IRB, and IACUC: How the Three Compare

Research administrators new to biosafety sometimes assume the IRB or IACUC already covers r/sNA risk; it does not. The three committees have distinct legal bases, review distinct risks, and are frequently required in combination on the same project:

IRB — reviews research involving human subjects, under the Common Rule and FDA human-subjects regulations. See IRB (Institutional Review Board).
IACUC — reviews research involving live vertebrate animals, under the Animal Welfare Act and the PHS Policy on Humane Care and Use of Laboratory Animals. See IACUC (Institutional Animal Care and Use Committee).
IBC — reviews research involving recombinant or synthetic nucleic acid molecules (and, at most institutions, biohazardous materials generally), under the NIH Guidelines and institutional biosafety policy.

A single project — for example, a gene-therapy study in an animal model that will progress toward a human clinical trial — can require sequential or parallel approval from all three: IACUC for the animal work, IBC for the recombinant vector, and eventually IRB (plus FDA) once the protocol moves to human subjects.

2025 Transparency Requirement

Under NIH Guide Notice NOT-OD-25-082 (issued March 2025), institutions are expected, effective for meetings held on or after June 1, 2025, to publicly post approved IBC meeting minutes (with appropriate redactions) rather than only making them available on request, which remains the standard for earlier meetings. NIH OSP separately publishes registered IBC rosters through its IBC Registration Management System.

Frequently Asked Questions

Does every research institution need an IBC?

Only institutions conducting research covered by the NIH Guidelines need a registered IBC. Because r/sNA techniques are now routine across molecular biology, most research universities and academic medical centers maintain one institution-wide, regardless of whether a specific project is NIH-funded — see the NIH Guidelines guide linked above for how institutions typically scope this.

Who can serve on an IBC?

Membership must collectively provide the expertise to assess r/sNA research risk, and must include at least two community members unaffiliated with the institution. Many IBCs also include a biosafety officer, a plant/animal biosafety expert where relevant, and representation from occupational health.

Is IBC approval the same as BSL assignment?

No. BSL (Biosafety Level) is the containment standard applied to a protocol; IBC approval is the governance action that reviews the protocol and assigns or confirms that containment level, among other conditions. See Biosafety Level (BSL).

References

NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, NIH Office of Science Policy (osp.od.nih.gov), Section IV-B (Institutional Biosafety Committee).
NIH Guide Notice NOT-OD-25-082, IBC meeting minutes transparency, effective June 1, 2025.
CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th edition.

Use in your systems

JATS XML <role> element

xml

<role vocab="credit"
      vocab-identifier="https://casrai.org/dictionary/"
      vocab-term="Institutional Biosafety Committee (IBC)"
      vocab-term-identifier="https://casrai.org/dictionary/term/institutional-biosafety-committee-ibc" />

Schema.org DefinedTerm (JSON-LD)

json

{
  "@context": "https://schema.org",
  "@type": "DefinedTerm",
  "@id": "https://casrai.org/dictionary/term/institutional-biosafety-committee-ibc",
  "name": "Institutional Biosafety Committee (IBC)",
  "identifier": "https://casrai.org/dictionary/term/institutional-biosafety-committee-ibc",
  "description": "A standing institutional committee, registered with the NIH Office of Science Policy under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, that reviews, approves, and provides ongoing oversight of research involving recombinant or synthetic nucleic acid molecules before such research may begin.",
  "inDefinedTermSet": "https://casrai.org/dictionary/domain/compliance-regulatory#set",
  "url": "https://casrai.org/dictionary/term/institutional-biosafety-committee-ibc",
  "sameAs": [],
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {
    "@id": "https://casrai.org/#organization"
  },
  "dateModified": "2026-07-18T02:12:04",
  "inLanguage": "en"
}